Literature DB >> 24582199

Cellular therapy for liver disease.

Robert C Huebert1, Jorge Rakela2.   

Abstract

Regenerative medicine is energizing and empowering basic science and has the potential to dramatically transform health care in the future. Given the remarkable intrinsic regenerative properties of the liver, as well as widespread adoption of regenerative strategies for liver disease (eg, liver transplant, partial hepatectomy, living donor transplant), hepatology has always been at the forefront of clinical regenerative medicine. However, an expanding pool of patients awaiting liver transplant, a limited pool of donor organs, and finite applicability of the current surgical approaches have created a need for more refined and widely available regenerative medicine strategies. Although cell-based therapies have been used extensively for hematologic malignant diseases and other conditions, the potential application of cellular therapy for acute and chronic liver diseases has only more recently been explored. New understanding of the mechanisms of liver regeneration and repair, including activation of local stem/progenitor cells and contributions from circulating bone marrow-derived stem cells, provide the theoretical underpinnings for the rational use of cell-based therapies in clinical trials. In this review, we dissect the scientific rationale for various modalities of cell therapy for liver diseases being explored in animal models and review those tested in human clinical trials. We also attempt to clarify some of the important ongoing questions that need to be addressed in order to bring these powerful therapies to clinical translation. Discussions will cover transplant of hepatocytes and liver stem/progenitor cells as well as infusion or stimulation of bone marrow-derived stem cells. We also highlight tremendous scientific advances on the horizon, including the potential use of induced pluripotent stem cells and their derivatives as individualized regenerative therapy for liver disease.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24582199      PMCID: PMC4212517          DOI: 10.1016/j.mayocp.2013.10.023

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  98 in total

1.  Feeder-free and serum-free production of hepatocytes, cholangiocytes, and their proliferating progenitors from human pluripotent stem cells: application to liver-specific functional and cytotoxic assays.

Authors:  Naoko Nakamura; Kumiko Saeki; Masami Mitsumoto; Satoko Matsuyama; Miwako Nishio; Koichi Saeki; Mamoru Hasegawa; Yoshiyuki Miyagawa; Hajime Ohkita; Nobutaka Kiyokawa; Masashi Toyoda; Hidenori Akutsu; Akihiro Umezawa; Akira Yuo
Journal:  Cell Reprogram       Date:  2012-03-02       Impact factor: 1.987

2.  Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis.

Authors:  Pau Sancho-Bru; José Altamirano; Daniel Rodrigo-Torres; Mar Coll; Cristina Millán; Juan José Lozano; Rosa Miquel; Vicente Arroyo; Juan Caballería; Pere Ginès; Ramon Bataller
Journal:  Hepatology       Date:  2012-04-23       Impact factor: 17.425

3.  Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis.

Authors:  Ja Kyung Kim; Young Nyun Park; Jin Seok Kim; Mi-Suk Park; Yong Han Paik; Jae-Yeon Seok; Yong Eun Chung; Hyun Ok Kim; Kyung Sik Kim; Sang Hoon Ahn; Do Young Kim; Myeong-Jin Kim; Kwan Sik Lee; Chae Yoon Chon; Soo Jeong Kim; Shuji Terai; Isao Sakaida; Kwang-Hyub Han
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

4.  Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure.

Authors:  Vishal Garg; Hitendra Garg; Arshi Khan; Nirupama Trehanpati; Ashish Kumar; Barjesh Chander Sharma; Puja Sakhuja; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2011-11-23       Impact factor: 22.682

5.  Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-β1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis.

Authors:  Le Yang; Na Chang; Xin Liu; Zhen Han; Tieping Zhu; Changyong Li; Lin Yang; Liying Li
Journal:  Am J Pathol       Date:  2012-05-17       Impact factor: 4.307

6.  Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice.

Authors:  Dong-Hun Woo; Suel-Kee Kim; Hee-Joung Lim; Jeonghoon Heo; Hyung Soon Park; Gum-Yong Kang; Sung-Eun Kim; Hyun-Ju You; Daniel J Hoeppner; Youngchul Kim; Heechung Kwon; Tae Hyun Choi; Joo Hee Lee; Su Hee Hong; Kang Won Song; Eun-Kyung Ahn; Josh G Chenoweth; Paul J Tesar; Ronald D G McKay; Jong-Hoon Kim
Journal:  Gastroenterology       Date:  2011-12-02       Impact factor: 22.682

7.  Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.

Authors:  James A Thomas; Caroline Pope; Davina Wojtacha; Andrew J Robson; Timothy T Gordon-Walker; Stephen Hartland; Prakash Ramachandran; Marielle Van Deemter; David A Hume; John P Iredale; Stuart J Forbes
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

8.  Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol.

Authors:  Yu-Fan Chen; Chien-Yu Tseng; Hsei-Wei Wang; Hung-Chih Kuo; Vincent W Yang; Oscar K Lee
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

9.  Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients.

Authors:  Zheng Zhang; Hu Lin; Ming Shi; Ruonan Xu; Junliang Fu; Jiyun Lv; Liming Chen; Sa Lv; Yuanyuan Li; Shuangjie Yu; Hua Geng; Lei Jin; George K K Lau; Fu-Sheng Wang
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

Review 10.  Model systems and experimental conditions that lead to effective repopulation of the liver by transplanted cells.

Authors:  David A Shafritz; Michael Oertel
Journal:  Int J Biochem Cell Biol       Date:  2010-01-18       Impact factor: 5.085

View more
  26 in total

1.  A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.

Authors:  Abhisek Mitra; Jun Yan; Liangfang Zhang; Shulin Li
Journal:  Transl Res       Date:  2018-10-19       Impact factor: 7.012

Review 2.  Proceedings: moving toward cell-based therapies for liver disease.

Authors:  Lisa C Kadyk; Lila R Collins; Neil J Littman; Maria T Millan
Journal:  Stem Cells Transl Med       Date:  2015-01-30       Impact factor: 6.940

3.  Etanercept blocks inflammatory responses orchestrated by TNF-α to promote transplanted cell engraftment and proliferation in rat liver.

Authors:  Preeti Viswanathan; Sorabh Kapoor; Vinay Kumaran; Brigid Joseph; Sanjeev Gupta
Journal:  Hepatology       Date:  2014-09-09       Impact factor: 17.425

Review 4.  Immunological aspects of liver cell transplantation.

Authors:  Felix Oldhafer; Michael Bock; Christine S Falk; Florian W R Vondran
Journal:  World J Transplant       Date:  2016-03-24

5.  Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes.

Authors:  Mladen I Yovchev; Joseph Locker; Michael Oertel
Journal:  J Hepatol       Date:  2016-02-05       Impact factor: 25.083

Review 6.  Regenerative Medicine and the Biliary Tree.

Authors:  Thiago M De Assuncao; Nidhi Jalan-Sakrikar; Robert C Huebert
Journal:  Semin Liver Dis       Date:  2017-02-15       Impact factor: 6.115

7.  Noninvasive 3-dimensional imaging of liver regeneration in a mouse model of hereditary tyrosinemia type 1 using the sodium iodide symporter gene.

Authors:  Raymond D Hickey; Shennen A Mao; Bruce Amiot; Lukkana Suksanpaisan; Amber Miller; Rebecca Nace; Jaime Glorioso; Michael K O'Connor; Kah Whye Peng; Yasuhiro Ikeda; Stephen J Russell; Scott L Nyberg
Journal:  Liver Transpl       Date:  2015-03-12       Impact factor: 5.799

Review 8.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

9.  Preclinical Application of Reduced Manipulated Processing Strategy to Collect Transplantable Hepatocytes: A Pilot and Feasibility Study.

Authors:  Ya-Hui Chen; Hui-Ling Chen; Cheng-Maw Ho; Hung-Yen Chen; Shu-Li Ho; Rey-Heng Hu; Po-Huang Lee; Mei-Hwei Chang
Journal:  J Pers Med       Date:  2021-04-21

10.  Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

Authors:  Rachele Ciccocioppo; Claudia C Dos Santos; Daniel C Baumgart; Giuseppina C Cangemi; Vincenzo Cardinale; Carolina Ciacci; Paolo De Coppi; Debashis Haldar; Catherine Klersy; M Cristina Nostro; Michael Ott; Lorenzo Piemonti; Alice A Tomei; Basak Uygun; Stefania Vetrano; Giuseppe Orlando
Journal:  Cytotherapy       Date:  2018-02-15       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.